期刊論文| 1. | 黃俊杰(20020600)。特別公課類型化及其課徵正義之研究。臺北大學法學論叢，50，101-143。 延伸查詢 |
| 2. | Schwartz, Teresa Moran(1991)。Consumer-Directed Prescription Drug Advertising and the Learned Intermediary Rule。Food Drug COSM. L.J.，46，829-830。  |
| 3. | 廖建瑜(20051200)。論醫師說明義務之建構與發展--兼評最高法院94年臺上字第2676號判決。成大法學，10，231-293。 延伸查詢 |
| 4. | Tietz, Gerald F.(1986)。Informed Consent in the Prescription Drug Context: The Special Case。Washington Law Review，61(2)，367-417。 |
| 5. | 陳汝吟(2004)。論網路DTC廣告之法律規範：以藥物DTC廣告對隱私權及産品責任影響爲例。玄奘法律學報，2，1-51。 延伸查詢 |
| 6. | 陳杰峰、王慈蜂(2009)。醫學文獻評讀概念、方法與等級介紹42，19-23。 延伸查詢 |
| 7. | Greene, Stephanie(2005)。False Claims Act Liability for Off- Label Promotion of Pharmaceutical Products。PENN，110，41。 |
| 8. | Herrmann, Mark、Bownas, Pearson(2009)。Keeping the Label Out of the Case。Northwestern University Law Review Colloquy，103，477-484。 |
| 9. | Johns, Margaret Z.(2007)。Informed Consent: Requiring Doctors to Disclose Off-Label Use Prescription and Conflicts of Interest。HASTINGS L.J.，58，967。 |
| 10. | Lansdale, Edward P.(2006)。Used As Directed? How Prosecutors Are Expanding the False Claims act to Police Pharmaceutical Off-Label Marketing。NEW ENG. L. REV.，41，159。 |
| 11. | Moyer, Cynthia A.(2005)。Off-Label Use and the Medical Negligence Standard Under Minnesota Law。WM. MITCHEL L. REV.，31，927。 |
| 12. | Noah, Lars,(2002)。Informed Consent and the Elusive Dichotomy Between Standard and Experimental Therapy。Am J.L. & MED.，28，361。 |
| 13. | O’Reilly,James、Dalai, Amy,(2003)。Off-Label or Out of Bounds? Prescriber and Marketer Liability for Unapproved Use of FDA-Approved Drugs。ANNALS HEALTH L.，12，295。 |
| 14. | Whitney, Daniel W.(2010)。Guide to Preemption of State-Law Claims Against Class III PMA Medical Devices。FOOD & DRUG L，65，113。 |
| 15. | Osborn, John E.,(2010)。Can I Tell You the Truth? A Comparative Perspective on Regulating Off-Label Scientific and Medical Information。YALE J. HEALTH POL'Y,L. & ETHICS ，10，299。 |
| 16. | Radley, David C.、Finkelstein, Stan N.、Stafford, Randall S.(2006)。Off-Label Prescribing Among Office-Based Physicians。ARCH. INTERN. MED.，166，1021。 |
| 17. | Schuck, Peter H.(1994)。Rethinking Informed Consent。YALE L.J.，103，899。 |
| 18. | Stafford, Randall S.(200803)。Perspective: Regulating Off-Label Drug Use: Rethinking the Role of the FDA。N. ENGL J MED.，358，1427-1429。 |
| 19. | Ahn, Andrea(2010)。Wyeth v. Levine: Moving Away from the Geier Trend。DENV. U. L. REV.，87，561。 |
| 20. | Altshuler, Matt、Creekpaum, J. Kyden、Fang, Jim,(2008)。Health Care Fraud。AM. CRIM. L.REV.，45，607。 |
| 21. | Anna Wilde Mathews、David Armstrong,(2004)。Pfizer Case Signals Tougher Action on Off-Label Drug Use。WALL ST.J.。 |
| 22. | Ausness, Richard C.(2008)。There’s Danger Here！: Liability for the Promotion and Marketing of Drug and Medical Devices for Off-Label Use。BROOK. L. REV.，73，1253。 |
| 23. | Ausness, Richard C.(2002)。Will More Aggressive Marketing Practices Lead to Greater Tort Liability for Prescription Drug Manufacturers?。WAKE FOREST L，37，97。 |
| 24. | Bird, James R.、Comment(1977)。Package Inserts for Prescription Drugs as Evidence in Medical Malpractice Suits。U. CHI. L. REV.，44，398。 |
| 25. | Coutinho, Santosh V.(2009)。License to Promote, Or Just What the Doctor Ordered? The New FDA Guidance on Dissemination of Off-Label Reprints by Pharmaceutical Companies。Temple Journal Science Technology & Environmental Law，28，279-306。 |